Cetuximab

Drug Profile

Cetuximab

Alternative Names: Anti-EGFR monoclonal antibody 225; C 225; ch 225; Erbitux; IMC-C225; LY-2939777

Latest Information Update: 24 Feb 2017

Price : $50

At a glance

  • Originator University of California System
  • Developer Array BioPharma; Bristol-Myers Squibb; Centre Jean Perrin; Eli Lilly; Merck KGaA; New York University School of Medicine; Novartis; Pierre Fabre; Roche; University Hospital Ghent; University of Michigan Comprehensive Cancer Center
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Epidermal growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Colorectal cancer; Head and neck cancer
  • Phase III Non-small cell lung cancer
  • Phase II Bladder cancer; Breast cancer; Gastric cancer; Mesothelioma; Rectal cancer
  • Phase Unknown Oesophageal cancer
  • No development reported Pancreatic cancer; Prostate cancer

Most Recent Events

  • 02 Nov 2016 Bristol-Myers Squibb terminates a phase II trial (Combination therapy) in Head and neck cancer in USA (NCT01488318)
  • 01 Jul 2016 Interim efficacy data from a phase III TAILOR study in metastatic colorectal cancer released by Merck
  • 06 Jun 2016 Phase-III clinical trials in Colorectal cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in Oceania, Asia, Europe, South America, North America (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top